---

Highlights of August 2023

 

1.      Agarwal’s Health Care Ltd focused on Eye health has raised US$80 million (INR 661 crores) from TPG Growth and Temasek, Singapore.

2.      CEPI, Gennova Biopharmaceuticals collaborate to develop saRNA vaccine for Disease X.

3.      Lupin acquires 2 diabetes brands from Boehringer.

4.      CrisprBits, Molbio Diagnostics collaborate to introduce CRISPR-based POC tests.

5.      Torrent joins fray for Hamied family stake in Cipla, up against Blackstone and Baring PE

6.      Sun Pharma is looking to fully acquire its Israel-based unit Taro Pharmaceutical in order to integrate the dermatology business with itself and keep it profitable amid increasing competition in the segment.

7.      LEO Pharma has signed an agreement to acquire US-listed Timber Pharmaceuticals. The deal represents a total transaction value of up to US$36.

8.      Sprint Bioscience licenses program to Day One Biopharmaceuticals.

9.      CNX Therapeutics buys Clinigen brands to expand hospital-injectable portfolio.

10.  Alnylam inks licensing deal with Agios Pharma.

11.  Ikena Oncology acquires Pionyr Immunotherapeutics.

12.  Alexion, AstraZeneca Rare Disease, enters agreement with Pfizer.

13.  Novo Nordisk to acquire obesity drug developer Inversago.

14.  Specialised Therapeutics has partnered with Netherlands-based company Treeway BV to commercialize TW001, a novel oral formulation of edaravone for the treatment of Amyotrophic Lateral Sclerosis.

Highlights at Aagami:

1.      New Project: Existing client from New York has appointed Aagami for supporting strategic Initiatives of their new subsidiary focused on Autoimmune diseases being proliferated post pandemic.

2.      Aagami CEO Dinesh Jain to attend BIO JAPAN 2023 in Yokohama, Japan (Oct 11-13) to promote client’s market ready Denosumab biosimilar.

3.      Aagami Vice-President to attend Bio-Europe 2023 in Munich, Germany (Nov 6-8).

INFOCUS: Select opportunities available:

For Partnering/Licensing/ Co-development:

1. Licensing available for Japan: Market ready Denosumab biosimilar to PROLIA^® & XGEVA^®.
2. Licensing/Co-development: Easy to apply world’s First Transdermal Tizanidine Patch for the Management of Spasticity. Impressive Phase 1 results. Ready to initiate Phase 2.  
3. Seeking Partnering/JV – Phase 2 Smart Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia. 
4. Seeking licensing/co-development partnerships: A single (monovalent) vaccine for Targeting Salmonella, ETEC / E. coli, Campylobacter, Shigella. Fulfills an unmet need for treating Bacterial Dysentery.

For Acquisition:

1. Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP etc.- for Next-generation biologics and substantial returns. 
2. Asset Sale -  Oral small molecule oral small molecule modulator of mutant RyR2 for the treatment of CPVT-1/ Heart Arrhythmia.

 Seeking Investment:

1. Seeking US$15 million for Phase-1 POC: Intranasal Rifampicin (Patented, Orphan Drug Designation) for neurodegenerative diseases (High ROI).
2. Seeking US$5 million: A single (monovalent) vaccine for Targeting Salmonella, ETEC / E. coli, Campylobacter, Shigella. Fulfills an unmet need for treating Bacterial Dysentery.
3. US$40 Million Series C: On the market, US FDA approved novel portable MRI Guided Treatment, Diagnosis and Screening, for Urology applications. California based client.
4. Seeking US$3 Million: Precision fermentation-based technology to produce Natural Soluble Melanin at a cost hundreds of times lower. The current round proceeds will be used to achieve milestone of making a market ready Sunscreen cream using Melanin, under Consumer Health & Wellness category.
5. Seeking US$5 million: Midwest US based Pharma with Phase 2 stage First-in-Class Non-Opioid Analgesic NCE for Pain Relief.